Pulse Biosciences Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 marked a pivotal quarter with accelerated clinical progress, strong feasibility data, and a sharpened focus on the nPulse cardiac catheter program. Financials showed increased investment in clinical trials, with ample liquidity to fund operations through key milestones.
-
The company is advancing proprietary nanosecond pulsed field ablation technology, targeting rapid, efficient AFib treatment with a single catheter system. Strong clinical data, robust IP, and a solid financial position support accelerated IDE enrollment and expansion into new indications, with pivotal regulatory milestones expected by early 2028.
-
Exceptional clinical results with nanosecond PFA technology are driving strong investigator interest and rapid IDE study enrollment, with enhanced mapping integration and a focus on strategic partnerships. Resource allocation is shifting toward the EP program, with increased R&D spending expected in 2026.
-
The conference highlighted major advances in nanosecond pulsed field ablation, with clinical data showing unprecedented success rates in atrial fibrillation treatment and rapid, efficient workflows. The company is well-funded, expanding its pipeline into cardiac surgery and oncology, and expects to complete key clinical trial enrollments in 2026.
-
Pulse Biosciences highlighted rapid progress in clinical and commercial development of its proprietary nsPFA technology, targeting large markets in electrophysiology, cardiac surgery, and thyroid ablation. IDE approvals, strong IP, and early commercialization position the company for significant milestones in 2026.
Fiscal Year 2025
-
Advanced nsPFA platform achieved strong clinical and commercial milestones in 2025, with robust cardiac and soft tissue ablation results, increased Q4 revenue, and a solid cash position. Pivotal trials and CE Mark submissions are planned for 2026, with FDA clearances expected in 2027.
-
Nanosecond PFA technology offers non-thermal, highly targeted ablation with strong IP protection and is advancing commercialization in thyroid, cardiac surgery, and EP markets. The company is financially positioned for growth, with a hybrid go-to-market strategy and rapid clinical progress in key indications.
-
Pulse Biosciences presented its proprietary nanosecond PFA technology, highlighting clinical and commercial progress in thyroid, surgical cardiac, and electrophysiology markets. The company is advancing pivotal studies, pursuing a hybrid market strategy, and expects rapid adoption due to significant procedural and safety advantages.
-
Q3 2025 saw initial commercial revenues, strong clinical progress, and pivotal trial launches for soft tissue and cardiac ablation devices. Cash use increased with expanded trials, and positive early outcomes support further adoption and market expansion.
-
A proprietary nsPFA platform is positioned to disrupt thyroid, cardiac surgery, and EP ablation markets with non-thermal, minimally invasive therapies. Clinical pilots, IDE submissions, and a hybrid go-to-market strategy support near-term growth, backed by strong financials.
-
Q2 2025 saw expanded clinical adoption and strong feasibility results for nsPFA devices, with costs rising due to organizational growth and clinical trial investments. Initial revenue from the Percutaneous Electrode is expected in H2 2025, and regulatory progress continues for cardiac devices.
-
Q1 2025 saw expanded clinical progress and commercial readiness for nsPFA technology, with strong cash reserves and increased expenses supporting pivotal studies and U.S. market entry. Early clinical data show high efficacy in thyroid and cardiac applications.
-
Pulse Biosciences presented its focus on nanosecond PFA, highlighting strong leadership, robust financials, and a proprietary, non-thermal ablation technology. Commercialization begins in 2025 for thyroid nodules, with pivotal studies in cardiac and electrophysiology markets and future expansion into oncology under evaluation.
-
Executives outlined a multi-year strategy to commercialize nanosecond PFA technology, targeting thyroid, cardiac surgery, and EP ablation markets with a strong financial position and proprietary IP. Early clinical data show rapid, effective, and safe procedures, supporting a disruptive market entry.
-
Nanosecond PFA offers a novel, safer, and more efficient ablation technology with broad clinical potential. Commercial launch for thyroid nodules is set for Q2 2025, with expansion into cardiac and EP markets, supported by strong IP, clinical data, and a robust balance sheet.
Fiscal Year 2024
-
Q4 2024 saw increased investment in clinical and commercial expansion, with net loss rising but cash reserves strengthened by warrant exercises. Early clinical data for nanosecond PFA devices in thyroid and cardiac applications are promising, supporting a robust 2025 outlook.
-
Advanced three core nano-PFA applications with positive early clinical and regulatory progress, raised $60M in a rights offering, and increased cash to $79M. GAAP net loss widened to $12.7M on higher expenses, with pivotal clinical trials planned for 2025.
-
Pulse Biosciences presented its differentiated nano PFA technology, highlighting clinical progress in thyroid and cardiac ablation applications. The company is advancing pivotal studies, leveraging a strong IP portfolio, and targeting aggressive market entry through specific regulatory pathways.
-
Q2 saw major clinical and regulatory milestones, including FDA breakthrough designation, first-in-human cases, and a successful $60M rights offering. Cash on hand is expected to fund operations into 2026 as pivotal trials for three product lines are planned for 2025.